Hangzhou Laihe Biotech Co., Ltd. (hereafter referred to as "Laihe Biotech") is a life science company specialized in R & D, manufacturing, marketing and service in point-of-care testing, monitoring and health technology industry, is committed to provide fast, accurate and reliable health detection products and services.

Founded by Dr returned from United States in February 2012, today Laihe Biotech have a team of experienced scientists researching and developing diagnostic products, and have already built an independent POCT platform which including various rapid test products like Cardiac Marker Series (cTnI, NT-proBNP, H-FABP, etc. ), Inflammation Series (ds-CRP, PCT, etc. ), Tumor Marker Series (AFP, CEA, etc. ), Diabetes Monitoring Series (HbA1c), Fertility Series (TORCH) and Infectious Diseases Series. We continue to be innovative, and promote in-vitro diagnostic products in a miniaturized, individualized, family-oriented and low-cost way.

History

2012 In August, Hangzhou Laihe Biotech Co., Ltd. Was registered in Hangzhou, China. And in the same year, we participated Binjiang 5050 Plan supported by government.

2013 Cooperated with Zhejiang University to develop new products

GMP and Medical Device Manufacturing Enterprise License certified

2014 Cardiac Marker Series and Drug of Abuse Series were finished registration.

Subsidiary was established for products distribution and promotion.

2015 In February, we got ISO 13485: 9001 and CE certificate, and the international business was in development.

2016 Core product (PCR) was launched. We received 7 new patents.

We believe in the credo, "Sincere, Pragmatic, Efficient and Innovative", which motivates us to develop on the basis of talented people and technology, continuously provide public health testing products and services...

We promise to provide After-sale Service & Quality Guarantee to every customer.

Buy it at your ease, use it at your comforts.